Press Release Archive

April 16, 2008 - Results from Largest Statin Study of Patients with Alzheimer's Disease Show Lipitor(R) Has No Significant Impact on Disease

(BUSINESS WIRE)--In a study in patients with mild-to-moderate Alzheimer’s disease (AD), the addition of Lipitor (atorvastatin calcium tablets) 80 mg to Aricept® (donepezil HCl) 10 mg showed no significant differences in cognition or global function (key measures of Alzheimer’s progression) compared to placebo plus Aricept 10 mg. Furthermore, no statistically significant differences were seen on various cognitive, behavioral

April 16, 2008 - Pfizer and AVANT Enter into Licensing and Development Agreement for Novel Therapeutic Vaccine Candidate for Brain Cancer

NEW YORK & NEEDHAM, Mass.--(BUSINESS WIRE)--NEW YORK

April 15, 2008 - Lyrica Reduced Pain of Fibromyalgia in Patients Regardless of Symptoms of Anxiety or Depression

Pfizer’s Lyrica reduced pain of fibromyalgia in patients regardless of whether they experienced symptoms of anxiety or depression at the beginning of the study, according to a pooled analysis presented today at the American Academy of Neurology annual meeting. The analysis, which looked at data pooled from previous clinical trials, also showed that patients’ self-reported improvements were more closely associated

April 14, 2008 - Pfizer Completes Tender Offer for Shares of Encysive Pharmaceuticals Inc.

(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) today announced that the subsequent offering period of the tender offer by its wholly-owned subsidiary, Explorer Acquisition Corp., to purchase all of the outstanding shares of common stock of Encysive Pharmaceuticals Inc. (NASDAQ: ENCY) at a purchase price of $2.35 per share, net to the seller in cash, without interest thereon and less any required withholding taxes, expired as of 5:00 p.m., New York

April 8, 2008 - Pfizer Statement on Exubera Labeling Update in the United States

(BUSINESS WIRE)--Pfizer Inc said today that it updated the US product labeling for EXUBERA® (insulin human [rDNA original]) Inhalation Powder to include a warning with safety information about lung cancer cases observed in patients who used Exubera. This update is based on an ongoing review of the data from the Exubera clinical trial program and post-marketing experience by Pfizer and the Food and Drug Administration (FDA)

April 7, 2008 - Pfizer Extends Subsequent Offering Period of Tender Offer for Shares of Encysive Pharmaceuticals

(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) announced today that Explorer Acquisition Corp., a wholly-owned subsidiary of Pfizer, has extended the subsequent offering period of its tender offer for all of the outstanding shares of common stock of Encysive Pharmaceuticals Inc. (NASDAQ: ENCY) to 5:00 p.m., New York City time, on April 14, 2008. Pursuant to the tender offer, Explorer Acquisition Corp. is offering to purchase shares of Encysive at

April 6, 2008 - Pfizer Reports Shares of Encysive Pharmaceuticals Inc. Tendered Pursuant to Guaranteed Delivery Procedures

(BUSINESS WIRE)--On April 1, 2008, Pfizer Inc (NYSE: PFE) announced results of its tender offer by its wholly-owned subsidiary, Explorer Acquisition Corp., to purchase all of the outstanding shares of common stock of Encysive Pharmaceuticals Inc. (NASDAQ: ENCY) at a purchase price of $2.35 per share, net to the seller in cash, without interest thereon and less any required withholding taxes. Pursuant to information received from the

April 1, 2008 - Pfizer Announces Discontinuation of Phase III Clinical Trial for Patients with Advanced Melanoma

(BUSINESS WIRE)--Pfizer Inc announced today the discontinuation of a Phase III clinical trial (A3671009), of single-agent tremelimumab (CP-675,206) in patients with advanced melanoma, after the review of interim data showed that the trial would not demonstrate superiority to standard chemotherapy. Pfizer has communicated with worldwide regulatory authorities and investigators regarding the discontinuation of the trial. Investigators

April 1, 2008 - Lipitor Provided an Unexpectedly Potent Heart Benefit in Patients with Chronic Stable Angina, According to New Study

(BUSINESS WIRE)--Pfizer announced today that Lipitor® (atorvastatin calcium) 80 mg showed unexpectedly potent reduction in myocardial ischemia (a condition defined by insufficient blood supply and oxygen to the heart) in patients with chronic stable angina (chest pain). These results were presented today at the annual meeting of the American College of Cardiology. Lipitor significantly reduced the average number of ischemic

April 1, 2008 - Pfizer Invites Public to View and Listen to Webcast of April 17 Conference Call with Analysts

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10am EDT on Thursday, April 17. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2008 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit

March 31, 2008 - Pfizer Successfully Completes Tender Offer for Shares of Encysive Pharmaceuticals Inc. and Announces Subsequent Offer Period

(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) announced today that Explorer Acquisition Corp., a wholly-owned subsidiary of Pfizer, has purchased all of the shares validly tendered and not withdrawn pursuant to its tender offer for all of the outstanding shares of common stock of Encysive Pharmaceuticals Inc. (NASDAQ: ENCY) at a purchase price of $2.35 per share, net to the seller in cash, without interest thereon and less any required withholding

March 31, 2008 - Spanish Appellate Court Rules in Pfizer's Favor, Upholds Lipitor Patent

(BUSINESS WIRE) Pfizer Inc said today that the Court of Appeal of Barcelona has upheld the company's enantiomer patent covering the calcium salt of atorvastatin, the active ingredient in Lipitor, reversing the lower court decision. The enantiomer patent expires in July 2010. The patent was challenged jointly by generic companies Laboratorios Cinfa S.A., Kern Pharma S.L., Laboratorios Alter S.A. and Laboratorios Belmac S.A., and is

March 27, 2008 - Pfizer Obtains Clearance from Federal Cartel Office of Germany for Acquisition of All Outstanding Shares of Encysive Pharmaceuticals Inc.; ``Regulatory Condition'' Now Satisfied

( Pfizer Inc (NYSE:PFE) announced today that it has obtained clearance from the Federal Cartel Office of Germany (FCO) in connection with the tender offer by its wholly-owned subsidiary, Explorer Acquisition Corp., to purchase all of the outstanding shares of common stock of Encysive Pharmaceuticals Inc. (NASDAQ: ENCY) at a purchase price of $2.35 per share, net to the seller in cash, without interest thereon and less any

March 26, 2008 - Pfizer Clears U.S. Antitrust Review for Acquisition of All Outstanding Shares of Encysive Pharmaceuticals Inc.

(BUSINESS WIRE) Pfizer Inc (NYSE:PFE) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) has expired in connection with the tender offer by its wholly-owned subsidiary, Explorer Acquisition Corp., to purchase all of the outstanding shares of common stock of Encysive Pharmaceuticals Inc. (NASDAQ: ENCY) at a purchase price of $2.35 per share, net to the seller in cash, without

March 20, 2008 - Federal Court of Appeal in Canada Upholds Lipitor Enantiomer Patent, Decision Prevents Launch of Generic Product by Ranbaxy until 2010

(BUSINESS WIRE) Pfizer Inc said today that the Federal Court of Appeal of Canada has reversed a lower court ruling that held that Pfizer’s enantiomer patent could not block generic manufacturer Ranbaxy Laboratories Limited from obtaining approval for a competitor product to Lipitor. The appellate court issued an order prohibiting regulatory approval of Ranbaxy’s product in Canada until Pfizer’s enantiomer (calcium salt)

March 18, 2008 - Pfizer Animal Health to Acquire Catapult Genetics and Bovigen

(BUSINESS WIRE) Pfizer Animal Health today announced it will acquire two market-leading livestock genomics companies: Catapult Genetics, Pty., Ltd., focused on developing and commercializing innovative livestock DNA tests and gene markers to assist global food producers, processors and retailers in improving profitability and quality in the global food chain; and Bovigen, LLC, which markets DNA

March 12, 2008 - Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at Healthcare Conference

(BUSINESS WIRE) Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Martin Mackay, President, Pfizer Global Research & Development, at the Lehman Brothers Global Healthcare Conference on Wednesday, March 19th at 10:45 a.m. Eastern Daylight Savings Time. To view and listen to the webcast, visit our web site homepage at www.pfizer.com and click on the “Lehman Brothers

March 11, 2008 - Pfizer's Waxman to Leave

(BUSINESS WIRE) Pfizer said today that Senior Vice President and General Counsel Allen Waxman is leaving the company for personal reasons. Mr. Waxman will remain outside counsel to Pfizer through a transition period. Pfizer said David Reid, currently Senior Vice President and Managing Director, will assume Mr. Waxman’s responsibilities on an interim basis while the company conducts a search for a permanent successor

March 10, 2008 - Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Martin Mackay, President, Pfizer Global Research & Development, at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference on Wednesday, June 11th at 10:40 a.m. Pacific Daylight Saving Time. To view and listen to the webcast, visit our web site homepage at www.pfizer.com and click on the

March 7, 2008 - Pfizer Wins Challenge to Two Main U.S. Patents for Celebrex by Generic Manufacturer Teva

(BUSINESS WIRE)--Pfizer Inc announced today that the Court of Appeals for the Federal Circuit has upheld the two main U.S. patents covering Celebrex, the company’s selective non-steroidal anti-inflammatory (NSAID) medicine used to treat pain and inflammation. The patents had been challenged by generic manufacturer Teva Pharmaceuticals USA. The panel ruled that the patents (Nos. 5,466,823 and 5,563,165) covering the

Press release archive foot note

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

Stay on top of Pfizer breaking news: Get News Alerts by RSS.

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

If you do not have Adobe^® Reader, download it here. It is available without charge from Adobe^®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.